TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Price, Quote, News and Overview
NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR - Currency: USD
TEVA Quote, Performance and Key Statistics
17.77
+0.52 (+3.01%)
The current stock price of TEVA is 17.77 USD. In the past month the price decreased by -1.66%. In the past year, price increased by 5.65%.
TEVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.95 | 729.65B | ||
| JNJ | JOHNSON & JOHNSON | 15.43 | 373.01B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.73 | 331.61B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.2 | 233.10B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.56 | 225.96B | ||
| MRK | MERCK & CO. INC. | 10.14 | 198.30B | ||
| PFE | PFIZER INC | 7.27 | 132.75B | ||
| SNY | SANOFI-ADR | 11.34 | 122.83B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.52B | ||
| GSK | GSK PLC-SPON ADR | 9.24 | 83.58B | ||
| ZTS | ZOETIS INC | 28.27 | 75.76B | ||
| HLN | HALEON PLC-ADR | 22.14 | 49.84B |
Related stock screener links
About TEVA
Company Profile
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Company Info
TEVA PHARMACEUTICAL-SP ADR
124 Dvora Hanevi'a St.
TEL AVIV-YAFO 49131 IL
CEO: Kare Schultz
Employees: 33892
Phone: 97239148213
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the stock price of TEVA PHARMACEUTICAL-SP ADR today?
The current stock price of TEVA is 17.77 USD. The price increased by 3.01% in the last trading session.
What is the ticker symbol for TEVA PHARMACEUTICAL-SP ADR stock?
The exchange symbol of TEVA PHARMACEUTICAL-SP ADR is TEVA and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is TEVA stock listed?
TEVA stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for TEVA PHARMACEUTICAL-SP ADR stock?
9 analysts have analysed TEVA and the average price target is 0.05 USD. This implies a price decrease of -99.71% is expected in the next year compared to the current price of 17.77. Check the TEVA PHARMACEUTICAL-SP ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TEVA PHARMACEUTICAL-SP ADR worth?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a market capitalization of 20.38B USD. This makes TEVA a Large Cap stock.
How many employees does TEVA PHARMACEUTICAL-SP ADR have?
TEVA PHARMACEUTICAL-SP ADR (TEVA) currently has 33892 employees.
What are the support and resistance levels for TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a support level at 16.78 and a resistance level at 17.26. Check the full technical report for a detailed analysis of TEVA support and resistance levels.
Is TEVA PHARMACEUTICAL-SP ADR (TEVA) expected to grow?
The Revenue of TEVA PHARMACEUTICAL-SP ADR (TEVA) is expected to grow by 4.36% in the next year. Check the estimates tab for more information on the TEVA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TEVA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TEVA, evaluating the profitability, health, valuation and growth aspects
- TEVA PHARMACEUTICAL-SP ADR (TEVA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TEVA PHARMACEUTICAL-SP ADR (TEVA) Sales and EPS estimates to see what analysts future expectations are.
- TEVA PHARMACEUTICAL-SP ADR (TEVA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TEVA PHARMACEUTICAL-SP ADR (TEVA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Chart to make your own analysis
- TEVA PHARMACEUTICAL-SP ADR (TEVA) Latest news and press-releases to stay up to date.
Does TEVA PHARMACEUTICAL-SP ADR (TEVA) stock pay dividends?
TEVA does not pay a dividend.
When does TEVA PHARMACEUTICAL-SP ADR (TEVA) report earnings?
TEVA PHARMACEUTICAL-SP ADR (TEVA) will report earnings on 2025-07-29, before the market open.
What is the Price/Earnings (PE) ratio of TEVA PHARMACEUTICAL-SP ADR (TEVA)?
The PE ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 7.08. This is based on the reported non-GAAP earnings per share of 2.51 and the current share price of 17.77 USD. Check the full fundamental report for a full analysis of the valuation metrics for TEVA.
What is the Short Interest ratio of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The outstanding short interest for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 3.39% of its float. Check the ownership tab for more information on the TEVA short interest.
TEVA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to TEVA. When comparing the yearly performance of all stocks, TEVA is one of the better performing stocks in the market, outperforming 75.3% of all stocks.
TEVA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TEVA. While TEVA is still in line with the averages on profitability rating, there are concerns on its financial health.
TEVA Financial Highlights
Over the last trailing twelve months TEVA reported a non-GAAP Earnings per Share(EPS) of 2.51. The EPS decreased by -4.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.35% | ||
| ROE | -20.54% | ||
| Debt/Equity | 2.59 |
TEVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 42% to TEVA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 4.61% and a revenue growth 4.36% for TEVA